Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société VYNE THERAPEUTICS INC.
01/07VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
01/05VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Co..
AQ
2020VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for ..
GL
2020VYNE THERAPEUTICS : Added to Nasdaq Biotechnology Index
AQ
2020VYNE THERAPEUTICS : Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (mino..
AQ
2020VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data f..
GL
2020VYNE THERAPEUTICS : to Present at the 32nd Annual Piper Sandler Healthcare Confe..
AQ
2020VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conf..
GL
2020VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
2020VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K..
AQ
2020VYNE THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provides Bu..
AQ
2020VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides B..
GL
2020VYNE THERAPEUTICS : to Report Third Quarter 2020 Financial Results on November 5..
AQ
2020VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November ..
GL
2020VYNE THERAPEUTICS : Announces Covered Status for ZILXI with Express Scripts
AQ
2020VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
2020VYNE THERAPEUTICS : Announces Covered Status for ZILXI™ (minocycline) with..
AQ
2020VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) wit..
GL
2020VYNE THERAPEUTICS : Announces ZILXI topical foam, 1.5% is Available in Pharmacie..
AQ
2020VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
2020VYNE THERAPEUTICS : Announces ZILXI™ (minocycline) topical foam, 1.5% is A..
AQ
2020VYNE THERAPEUTICS : Announces ZILXI™ (minocycline) topical foam, 1.5% Avai..
PR
2020VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is ..
GL
2020VYNE THERAPEUTICS : to Host Physician Symposium on AMZEEQ and ZILXI
AQ
2020VYNE THERAPEUTICS : to Host Physician Symposium on AMZEEQ® and ZILXI™
AQ
2020VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
GL
2020VYNE THERAPEUTICS : Announces the Appointment of Patrick G. LePore to its Board ..
AQ
2020VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers, Regulation F..
AQ
2020VYNE THERAPEUTICS : Announces the Appointment of Patrick G. LePore to its Board ..
AQ
2020VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Boar..
GL
2020VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitz..
GL
2020MENLO THERAPEUTICS : Announces Completion of Corporate Name Change to VYNE Thera..
AQ
2020MENLO THERAPEUTICS : Announces Completion of Corporate Name Change to VYNE Thera..
PR
2020MENLO THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
2020MENLO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
2020MENLO THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-..
AQ
2020Menlo Reports Second Quarter 2020 Financial Results and Provides Business Upd..
GL
2020MENLO THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (f..
AQ
2020Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August ..
GL
2020MENLO THERAPEUTICS INC. : Changes in Registrant's Certifying Accountant, Financi..
AQ
2020MENLO THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial ..
AQ
2020MENLO THERAPEUTICS : Announces Pricing of Offering of Common Stock
AQ
2020Menlo Therapeutics Announces Pricing of Offering of Common Stock
GL
2020Menlo Therapeutics Announces Proposed Offering of Common Stock
GL
2020MENLO THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 fo..
GL
2020MENLO THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topica..
GL
2020MENLO THERAPEUTICS : Announces Covered Status for AMZEEQ topical foam, 4%, on Ad..
AQ
2020Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical..
GL
2020Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference
GL
2020ROBBINS GELLER RUDMAN & DOWD LLP : Announce Proposed Settlement in the Menlo The..
BU
2020MENLO THERAPEUTICS : Steven Basta Joins the DermBiont, Inc. Board of Directors
AQ
2020MENLO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
2020MENLO THERAPEUTICS INC. : Results of Operations and Financial Condition, Financi..
AQ
2020Menlo Reports First Quarter 2020 Financial Results and Provides Business Upda..
GL
2020MENLO THERAPEUTICS : Financial Statements and Exhibits (form 8-K/A)
AQ
2020Menlo Therapeutics to Report First Quarter 2020 Financial Results on May 11
GL
2020MENLO THERAPEUTICS : and Cutia Therapeutics Enter into Exclusive License Agreeme..
AQ
2020MENLO THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation..
AQ
2020Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreem..
GL
2020MENLO THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020MENLO THERAPEUTICS INC. : Changes in Registrant's Certifying Accountant, Amendme..
AQ
2020Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serl..
GL
2020Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces ..
GL
2020MENLO THERAPEUTICS INC. : Change in Directors or Principal Officers, Amendment o..
AQ
2020Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer
GL
2020MENLO THERAPEUTICS : Provides a Business Update in the Context of COVID-19
AQ
2020Menlo Therapeutics Provides a Business Update in the Context of COVID-19
GL
2020MENLO THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
2020Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Yea..
GL
2020MENLO THERAPEUTICS : and Foamix Pharmaceuticals Complete Merger, Creating a Comb..
AQ
2020MENLO THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion..
AQ
2020Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Com..
GL
2020MENLO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
1  2Next